America October 4, 2024
SEC Fines Cassava $40M for Misleading Alzheimer’s Drug Trial Data
Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two former executives have agreed to pay over $40 million to resolve U.S.…
America October 4, 2024
Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two former executives have agreed to pay over $40 million to resolve U.S.…
By USA Herald
America June 27, 2024
The U.S. Securities and Exchange Commission has filed a lawsuit against BorrowMoney.com Inc. and its CEO, Aldo Piscitello, accusing them…
By Rihem Akkouche